Showing results (51-60 of 141) with videos related to
Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2014
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du MyélomeMurielle Roussel, Valérie Lauwers-Cances, Nelly Robillard, et al.European Journal of Haematology|July 21, 2018
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practiceEvangelos Terpos, Eirini Katodritou, Javier de la Rubia, et al.Blood|September 24, 2025
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trialFrançoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman, et al.European Journal of Haematology|October 26, 2011
Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du MyélomeIbrahim Yakoub-Agha, Jean-Yves Mary, Cyrille Hulin, et al.Frontiers in Oncology|November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myelomaLaura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.Blood|July 29, 2006
Maintenance therapy with thalidomide improves survival in patients with multiple myelomaMichel Attal, Jean-Luc Harousseau, Serge Leyvraz, et al.Haematologica|August 28, 2025
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY studyThomas Chalopin, Cyrille Hulin, Bruno Royer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survivalHervé Avet-Loiseau, Michel Attal, Loic Campion, et al.Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.Journal of Thrombosis and Haemostasis : JTH|June 16, 2025
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trialEmilie Chalayer, Corinne Frere, Elisabeth Daguenet, et al.Pageof 15